Karius Revolutionizes Infectious Disease Diagnostics with $100M Funding Boost
May 3, 2024, 9:33 pm
Location: Canada, British Columbia, Vancouver
Employees: 501-1000
Founded date: 2012
Total raised: $846.1M
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Founded date: 2000
Karius, a genomic diagnostics powerhouse, has secured a whopping $100 million in Series C funding to expand its groundbreaking Karius Test. This test, a game-changer in infectious disease diagnosis, uses cutting-edge genomic analysis and AI to detect over 1,000 pathogens from just one blood sample.
The funding round, co-led by Khosla Ventures, 5AM Ventures, and Gilde Healthcare, also saw support from existing investors like Softbank Vision Fund 2 and General Catalyst. This injection of cash will fuel Karius' mission to transform infectious disease diagnostics and make the Karius Test more accessible to healthcare providers beyond hospital settings.
The recent appointment of three new board members, including Alex Morgan, M.D., Ph.D., Joep Muijrers, Ph.D., and Andrew Booth, further strengthens Karius' leadership team. These additions, along with recent positive outcomes from the PICKUP1 trial, highlight the potential of the Karius Test to revolutionize patient care and treatment.
With over 400 U.S. hospitals already utilizing the Karius Test, Karius aims to increase accessibility and unlock new possibilities with this funding boost. CEO Alec Ford emphasizes the urgent need for faster diagnostic solutions, especially for cancer patients at risk of deadly infections. The Karius Test's ability to rapidly identify pathogens can save lives and healthcare resources, making this $100 million investment a critical step towards improving patient outcomes and advancing healthcare innovation.
The funding round, co-led by Khosla Ventures, 5AM Ventures, and Gilde Healthcare, also saw support from existing investors like Softbank Vision Fund 2 and General Catalyst. This injection of cash will fuel Karius' mission to transform infectious disease diagnostics and make the Karius Test more accessible to healthcare providers beyond hospital settings.
The recent appointment of three new board members, including Alex Morgan, M.D., Ph.D., Joep Muijrers, Ph.D., and Andrew Booth, further strengthens Karius' leadership team. These additions, along with recent positive outcomes from the PICKUP1 trial, highlight the potential of the Karius Test to revolutionize patient care and treatment.
With over 400 U.S. hospitals already utilizing the Karius Test, Karius aims to increase accessibility and unlock new possibilities with this funding boost. CEO Alec Ford emphasizes the urgent need for faster diagnostic solutions, especially for cancer patients at risk of deadly infections. The Karius Test's ability to rapidly identify pathogens can save lives and healthcare resources, making this $100 million investment a critical step towards improving patient outcomes and advancing healthcare innovation.